RxDoctor Payments Data

Jerrie Smithwick

Nurse Practitioner · San Angelo, TXNPI 1881875698

Payments from drug & device makers

$962in general payments, 2019–2025

Across 32 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$308
  • Lilly USA, LLC$226
  • AbbVie$160
  • AstraZeneca$62
  • Sumitomo Pharma America, Inc.$40
  • Eisai Inc.$36
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$962 in reported general payments places this provider in the 75th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$172,498
Medicare patients
232
Services billed
3,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide168$198,718
EliquisApixaban52$70,777
MyrbetriqMirabegron41$38,299
JanuviaSitagliptin Phosphate26$27,747
MounjaroTirzepatide13$17,185
LinzessLinaclotide16$16,015
GemtesaVibegron14$9,965
PremarinEstrogens, Conjugated23$7,316
Breo ElliptaFluticasone/Vilanterol15$6,066
Levothyroxine Sodium487$5,873
Potassium Chloride148$5,561
Tresiba Flextouch U-100Insulin Degludec13$5,453
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$4,942
Memantine Hcl62$4,617
SymbicortBudesonide/Formoterol Fumarate18$3,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$308$198,718168 claims
Lilly USA, LLCMounjaro$226$17,18513 claims
AbbVieLinzess$160$16,01516 claims
Sumitomo Pharma America, Inc.Gemtesa$40$9,96514 claims
AstraZenecaSymbicort$62$3,89818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →